on Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) reacquired rights to the development and commercialization of giroctocogene fitelparvovec, an investigational gene therapy candidate for moderate-to-severe hemophilia A, which it co-developed and licensed to Pfizer Inc (NYSE:PFE).
Pfizer has decided to terminate the global collaboration and license agreement between the parties. Sangamo intends to explore all possibilities to improve the program, including looking for a potential new cooperation partner.
Also read: FDA approves Pfizer’s second hemophilia drug after six months
In July 2024, Pfizer announced the results of the Phase 3 AFFINE trial of the gyroctocogen fitelparvovec, which showed that the trial met the primary and key secondary superiority objectives compared to prophylaxis.
“…we believe it is well positioned for regulatory filings and potential commercialization,” said Sandy Macrae, Sangamo Therapeutics’ chief executive officer. “While we were surprised and extremely disappointed by Pfizer’s decision to end our collaboration so close to the expected BLA and MAA filings…”
The collaboration and license agreement with Pfizer will terminate on April 21, 2025. All trial participants will continue to be followed as planned during the transition period.
Sangamo believes that the recently announced partnership with Roche Holdings AG (OTC:RHHBY) Genentech and Astellas Pharma Inc (OTC:ALPMF) (OTC:ALPMY) and advanced business development discussions for its Fabry gene therapy program will allow it to chart a path forward for its neurological genomic medicine pipeline.
The company is preparing to initiate the expected enrollment of patients in a Phase 1/2 study of ST-503 for idiopathic small fiber neuropathy in mid-2025 and submit an expected application for clinical trial approval for the prion disease program in the fourth quarter of 2025, each subject to securing additional funding.
Price of shares: Shares of SGMO traded down 54.70% to $1.106 during the pre-market session last checked on Tuesday.
Read on:
Next: Transform your trading with Benzinga Edge’s unique market trading ideas and tools. Click now to access unique insights that can get you ahead in today’s competitive market.
Get the latest stock analysis from Benzingo?
This article Sangamo Therapeutics Shares Fall as Pfizer Terminates Hemophilia Gene Therapy Pact originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
